Tesamorelin
Visceral Fat Reduction & Growth Hormone-Releasing Hormone Science
STRONG HUMAN EVIDENCE
APPROVED FOR HIV-ASSOCIATED LIPODYSTROPHY
NOT AN APPROVED USE
What Is Tesamorelin?
Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH), also called growth hormone-releasing factor (GHRF).
Rather than supplying growth hormone directly, tesamorelin acts on GHRH receptors in the pituitary gland and stimulates the body's own pulsatile release of growth hormone (GH). Growth hormone subsequently influences several metabolic pathways, including production of insulin-like growth factor-1 (IGF-1) and the metabolism of adipose tissue.
Unlike many peptides commonly discussed in wellness and body-composition settings, tesamorelin is an FDA-approved prescription medication. It was first approved in the United States in 2010. Its approved indication is specifically for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.
Important: FDA approval of tesamorelin does not mean it is FDA-approved as a general weight-loss, bodybuilding, anti-aging, or abdominal-fat medication for people without HIV-associated lipodystrophy.
Why Are Researchers Interested?
Tesamorelin is scientifically interesting because visceral fat is biologically different from the subcutaneous fat found directly beneath the skin. Visceral adipose tissue surrounds internal abdominal organs and has been associated with metabolic abnormalities. Researchers have therefore studied whether stimulating physiologic GH secretion with tesamorelin can selectively influence visceral adipose tissue while limiting effects on subcutaneous fat and overall body weight. Areas of investigation have included:
Large randomized clinical trials have demonstrated reductions in visceral adipose tissue in the population for which tesamorelin was developed.
What The Research Suggests
Visceral Fat Reduction Is Supported by Human Clinical Trials
Tesamorelin differs significantly from many investigational peptides because its effects on visceral adipose tissue have been evaluated in large randomized, placebo-controlled human trials.
One 12-month study included 404 adults with HIV and excess abdominal fat. During the first six months, visceral adipose tissue decreased approximately 10.9% with tesamorelin compared with 0.6% with placebo. Participants who continued treatment for 12 months experienced approximately an 18% reduction from baseline.
A pooled analysis of two Phase 3 trials included 806 participants and found a treatment effect of approximately 15.4% reduction in visceral adipose tissue at 26 weeks compared with placebo. These clinical trials formed an important part of the evidence supporting tesamorelin's approved use.
Tesamorelin Targets Visceral Fat — Not General Weight Loss
This distinction is especially important. The current FDA-approved prescribing information states that EGRIFTA WR is not indicated for weight-loss management and describes tesamorelin as having a weight-neutral effect.
In other words, reduced visceral fat does not necessarily mean substantial weight loss on the scale. Clinical studies found changes in visceral abdominal fat and waist-related measurements without establishing tesamorelin as a conventional obesity or weight-loss medication.
Visceral-Fat Reduction May Be Lost After Treatment Stops
Clinical research has also demonstrated an important limitation. In longer-term trials, participants who continued tesamorelin maintained reductions in visceral adipose tissue, while participants who discontinued treatment experienced reaccumulation of visceral fat.
This suggests that tesamorelin does not permanently “reset” abdominal fat biology after a course of treatment. Its effects appear, at least in the studied population, to depend substantially on continued therapy.
Tesamorelin Raises Growth Hormone and IGF-1 Activity
Tesamorelin does not function like a conventional stimulant or direct fat-dissolving compound. It activates the body's GHRH → GH → IGF-1 pathway.
The FDA label explains that GHRH stimulates pituitary cells to produce and release endogenous growth hormone. GH then acts on numerous tissues and produces some of its biological effects through IGF-1.
Clinical trials consistently demonstrated increased IGF-1 during tesamorelin treatment. That mechanism helps explain both its biological effects and several of its safety considerations.
Liver Fat Is an Active Area of Research
Tesamorelin has also been studied for liver fat in people living with HIV. A randomized trial involving 50 adults with HIV and abdominal fat accumulation found that six months of tesamorelin significantly reduced visceral adipose tissue and produced a modest reduction in liver fat compared with placebo.
A later randomized, double-blind study examined 61 people with HIV and fatty liver disease. After 12 months, tesamorelin produced an absolute liver-fat reduction of approximately 4.1 percentage points compared with placebo, corresponding to a relative reduction of approximately 37% from baseline.
These findings are scientifically important, but tesamorelin is not currently FDA-approved as a treatment for fatty liver disease.
Evidence At A Glance
HIV-Associated Visceral Fat Reduction
Randomized Phase 3 clinical trials demonstrated meaningful reductions in visceral adipose tissue in adults with HIV-associated abdominal fat accumulation.
General Weight Loss
Current FDA labeling specifically states that tesamorelin is not indicated for weight-loss management and has a weight-neutral effect.
General Visceral-Fat Reduction Outside HIV
Clinical evidence supporting approval is specific to adults with HIV-associated lipodystrophy.
Liver Fat
Randomized trials in people living with HIV have demonstrated reductions in hepatic fat, but further investigation is required.
Longevity / Anti-Aging
Tesamorelin's effects on GH and IGF-1 should not be interpreted as proof of anti-aging or lifespan-extension benefits.
Safety & Limitations
Because tesamorelin stimulates endogenous growth hormone and increases IGF-1, its safety considerations differ substantially from those of a simple weight-loss medication. Current FDA prescribing information identifies several important warnings and precautions.
Elevated IGF-1
Tesamorelin increases serum IGF-1. FDA notes that the consequences of prolonged elevation of IGF-1 are unknown, and the approved label recommends monitoring IGF-1 during treatment.
Malignancy Considerations
Because growth hormone and IGF-1 are involved in cellular growth pathways, malignancy is an important clinical consideration. The current prescribing information lists active malignancy as a contraindication. For people with previous malignancy, the FDA labeling states that the cancer should be inactive and treatment completed before therapy is considered.
This does not mean tesamorelin has been proven to cause cancer. Rather, stimulation of the GH/IGF-1 pathway creates a biological reason for caution in patients with malignancy.
Glucose Intolerance and Diabetes
Tesamorelin can affect glucose metabolism. The FDA warns that glucose intolerance or diabetes may develop, and glucose should be evaluated before and during therapy.
Some clinical studies did not identify major long-term differences in glucose measures, but individual susceptibility remains an important consideration.
Fluid Retention
Growth-hormone-related effects can include fluid retention. Reported effects can include edema, joint discomfort, muscle discomfort, and carpal tunnel syndrome.
Hypersensitivity and Injection-Site Reactions
Hypersensitivity reactions have occurred during clinical studies. Commonly reported adverse reactions with the FDA-approved product include arthralgia, injection-site redness, injection-site itching, pain in the extremities, peripheral edema, and myalgia.
Contraindications
Current FDA labeling lists EGRIFTA WR as contraindicated in patients with disruption of the hypothalamic-pituitary axis, active malignancy, known hypersensitivity to tesamorelin or product ingredients, and pregnancy.
Regulatory Status
Yes — for a specific indication. Tesamorelin received its initial U.S. approval in 2010. The current FDA-approved indication for EGRIFTA WR is reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.
Tesamorelin is not FDA-approved specifically for general weight loss, obesity treatment, cosmetic abdominal-fat reduction, bodybuilding, muscle building, athletic performance, anti-aging, longevity, fatty liver disease, or general metabolic optimization. The current label explicitly states that it is not indicated for weight-loss management.
Current FDA-Approved Formulations
As of September 2026, FDA's Purple Book lists tesamorelin under BLA 022505. Two prescription formulations are currently listed: EGRIFTA SV (2 mg) and EGRIFTA WR (11.6 mg). The original 1 mg EGRIFTA presentation is listed as discontinued.
The newer EGRIFTA WR formulation received FDA supplemental approval in 2025. FDA labeling emphasizes that EGRIFTA WR and EGRIFTA SV have different formulations and administration requirements and are not interchangeable.
Regulatory Status: FDA-Approved for a Specific Indication — Tesamorelin is FDA-approved for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It is not FDA-approved for general weight loss, obesity management, anti-aging, bodybuilding, or general cosmetic visceral-fat reduction.
Tesamorelin vs. Human Growth Hormone
Tesamorelin and human growth hormone interact with the same broader endocrine system, but they are not interchangeable treatments.
Tesamorelin
A synthetic analog of the body's natural growth hormone-releasing hormone. It stimulates the pituitary gland to release the body's own growth hormone in a more physiologic pulsatile pattern.
Human Growth Hormone (hGH)
Growth hormone itself. Administering recombinant growth hormone introduces the hormone directly rather than stimulating its natural release through GHRH receptors.
Why the Difference Matters: Tesamorelin works upstream by stimulating endogenous GH secretion. Growth hormone acts directly on GH receptors after administration. Both can influence IGF-1 and metabolic pathways, but evidence involving hGH should not automatically be presented as evidence for tesamorelin, and vice versa.
Research & Publications
Current FDA Prescribing Information — EGRIFTA WR
U.S. Food and Drug Administration / DailyMed — Current 2026 Label
Current prescribing information covering the FDA-approved indication, limitations of use, mechanism of action, contraindications, warnings, adverse reactions, and clinical studies.
View Current EGRIFTA WR Prescribing InformationFDA EGRIFTA WR Prescribing Information
U.S. Food and Drug Administration — 2025 Label
Official FDA prescribing information for the current EGRIFTA WR formulation.
View FDA Prescribing InformationMetabolic Effects of a Growth Hormone-Releasing Factor in Patients With HIV
New England Journal of Medicine — 2007
A randomized trial of 412 adults with HIV-associated abdominal fat accumulation found significant reduction in visceral adipose tissue with tesamorelin compared with placebo, along with changes in lipid measures.
View on PubMedTesamorelin in HIV-Associated Abdominal Fat Accumulation
Journal of Acquired Immune Deficiency Syndromes — 2010
A 12-month randomized study evaluating visceral adipose tissue, body composition, IGF-1, metabolic measures, safety, and what occurred when treatment was discontinued.
View on PubMedPooled Analysis of Two Phase 3 Tesamorelin Trials
Journal of Clinical Endocrinology & Metabolism — 2010
A pooled analysis involving 806 adults with HIV-associated excess abdominal fat. The study demonstrated a significant reduction in visceral adipose tissue compared with placebo.
View on PubMedLong-Term Safety and Visceral-Fat Effects
AIDS — 2008
Examined tesamorelin treatment over 52 weeks and found sustained reductions in visceral adipose tissue during continued treatment, with visceral fat reaccumulating after discontinuation.
View on PubMedTesamorelin, Visceral Fat and Liver Fat
JAMA — 2014
A randomized, placebo-controlled trial examining visceral adipose tissue and hepatic fat in adults with HIV and abdominal fat accumulation.
View on PubMedTesamorelin and Fatty Liver Disease in HIV
The Lancet HIV — 2019
A randomized, double-blind study evaluating tesamorelin in adults with HIV and fatty liver disease. Researchers observed a significant reduction in hepatic fat compared with placebo, while noting that additional research was needed to determine long-term clinical effects.
View on PubMedFDA Purple Book — Tesamorelin
U.S. Food and Drug Administration
FDA biologic-product listing documenting EGRIFTA, EGRIFTA SV, EGRIFTA WR, BLA 022505, and tesamorelin's original November 2010 approval.
View FDA Purple Book RecordTesamorelin has substantially stronger human clinical evidence than many peptides commonly discussed in wellness medicine because it has undergone large randomized clinical trials and has an FDA-approved therapeutic indication.
However, that approval is specific. Tesamorelin is FDA-approved for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.
Its approved indication should not be generalized to routine obesity treatment, cosmetic abdominal-fat reduction, bodybuilding, anti-aging, longevity, or general metabolic optimization. Research into liver fat and other metabolic applications remains scientifically interesting but should be distinguished from established FDA-approved treatment uses.
This page is provided for educational purposes only. Tesamorelin is not offered for sale, prescription, or distribution through this website.